Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Kald Abdallah

Showing results (1-10 of 6) with videos related to

Pageof 1
Sort By:
Plos One|February 3, 2017
Assessment of a prognostic model, PSA metrics and toxicities in metastatic castrate resistant prostate cancer using data from Project Data Sphere (PDS)Bethany Pitcher, Leila Khoja, Robert J Hamilton, et al.
Seminars in Oncology|November 16, 2010
Development of ipilimumab: contribution to a new paradigm for cancer immunotherapyAxel Hoos, Ramy Ibrahim, Alan Korman, et al.
Cancer Journal (Sudbury, Mass.)|March 25, 2022
Clinical Evidence Generation During a Pandemic: Lessons Learned for Sustaining ProgressDonna R Rivera, Paul G Kluetz, Kald Abdallah, et al.
The Lancet. Oncology|December 17, 2016
Estimation of tumour regression and growth rates during treatment in patients with advanced prostate cancer: a retrospective analysisJulia Wilkerson, Kald Abdallah, Charles Hugh-Jones, et al.
JCO Clinical Cancer Informatics|January 19, 2019
A DREAM Challenge to Build Prediction Models for Short-Term Discontinuation of Docetaxel in Metastatic Castration-Resistant Prostate CancerFatemeh Seyednasrollah, Devin C Koestler, Tao Wang, et al.
The Lancet. Oncology|November 20, 2016
Prediction of overall survival for patients with metastatic castration-resistant prostate cancer: development of a prognostic model through a crowdsourced challenge with open clinical trial dataJustin Guinney, Tao Wang, Teemu D Laajala, et al.
Pageof 1

Showing results (1-10 of 6) with videos related to

Sort By:
Pageof 1
Plos One|February 3, 2017
Assessment of a prognostic model, PSA metrics and toxicities in metastatic castrate resistant prostate cancer using data from Project Data Sphere (PDS)Bethany Pitcher, Leila Khoja, Robert J Hamilton, et al.
Seminars in Oncology|November 16, 2010
Development of ipilimumab: contribution to a new paradigm for cancer immunotherapyAxel Hoos, Ramy Ibrahim, Alan Korman, et al.
Cancer Journal (Sudbury, Mass.)|March 25, 2022
Clinical Evidence Generation During a Pandemic: Lessons Learned for Sustaining ProgressDonna R Rivera, Paul G Kluetz, Kald Abdallah, et al.
The Lancet. Oncology|December 17, 2016
Estimation of tumour regression and growth rates during treatment in patients with advanced prostate cancer: a retrospective analysisJulia Wilkerson, Kald Abdallah, Charles Hugh-Jones, et al.
JCO Clinical Cancer Informatics|January 19, 2019
A DREAM Challenge to Build Prediction Models for Short-Term Discontinuation of Docetaxel in Metastatic Castration-Resistant Prostate CancerFatemeh Seyednasrollah, Devin C Koestler, Tao Wang, et al.
The Lancet. Oncology|November 20, 2016
Prediction of overall survival for patients with metastatic castration-resistant prostate cancer: development of a prognostic model through a crowdsourced challenge with open clinical trial dataJustin Guinney, Tao Wang, Teemu D Laajala, et al.
Pageof 1